Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today the completion of enrollment in its Phase 2 trial of GKT831 in patients with Primary Biliary Cholangitis (PBC). The study enrolled a total of 111 patients in nine countries, exceeding the initial target of 102 subjects.
More information on
